The current status of CLL treatment
Results of CheckMate 039 trial of nivolumab in combination with ipilimumab for Hodgkin lymphoma
Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
Can the dream of affordable cancer care come true?
An audit of infusion-related reactions with biosimilar rituximab in London